Study researchers noted that the findings suggest the association between anxiety and improved OS was at least partly related to the higher incidence of irAEs, which implies that, in people with an ...

The treatment effects on PFS were consistent regardless of modeling approach and for both targeted and nontargeted therapies.

Funding accounted for 34.5 percent of total financial assistance requested in campaigns initiated between Jan. 1, 2021, and Feb. 28, 2023.

Results of the CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in renal cell carcinoma, were presented at JADPRO 2025.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

A review of EMR data from younger and older women with breast cancer noted that social support was not consistently documented among patients.

Researchers sought to determine whether survival outcomes for patients with early breast cancer was better with NACT or ACT when pCR was not achieved.

Researchers assessed the effectiveness of a modified SUNTRAC to identify risk of skin cancer in solid organ transplant recipients.

Investigators presented initial results from the phase 3 RAMPART trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma.

Thrombosis occurs in more than 1 in 10 adults receiving PEGylated asparaginase (Asp)–based therapy for acute lymphoblastic leukemia (ALL), with a 4-fold ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

Increase seen in overall survival, especially among those with HER2+-positive cancers, with median increase of more than 10 months.